Fosamax is a type of medication known as a bisphosphonate, prescribed for the treatment of bone loss and osteoporosis. In October of 2010 the FDA required all manufacturers of bisphosphonates to include on their label a warning that an increased risk of thigh fractures, specifically low-energy femoral shaft and subtrochanteric fractures, are associated with the drug. Recently, the FDA announced another ongoing safety review for this drug, after studies indicated an increased risk of esophageal cancer linked to the drug. Beasley Allen attorney Chad Cook has been selected to the Plaintiff Steering Committee for the consolidated litigation surrounding Fosamax and femur fractures.
This material is for informational purposes only and does not constitute legal advice. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers.
About Legal Briefs
Legal Briefs addresses various topics of public interest including recalls, public safety, breaking news and important verdicts and settlements.